NasdaqGS - Nasdaq Real Time Price USD

Bioventus Inc. (BVS)

6.80

+0.21

+(3.19%)

At close: May 8 at 4:00:01 PM EDT

6.45

-0.35

(-5.15%)

Pre-Market: 5:13:23 AM EDT

Bioventus First Quarter 2025 Earnings: EPS Beats Expectations

Bioventus ( NASDAQ:BVS ) First Quarter 2025 Results Key Financial Results Revenue: US$123.9m (down 4.3% from 1Q 2024...

Simply Wall St. 2 days ago

BVS
+3.19%
Bioventus Inc (BVS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Divestitures

Bioventus Inc (BVS) reports strong organic growth and EPS increase despite revenue decline from divestitures.

GuruFocus.com 2 days ago

BVS
+3.19%
Q1 2025 Bioventus Inc Earnings Call

Q1 2025 Bioventus Inc Earnings Call

Thomson Reuters StreetEvents 2 days ago

BVS
+3.19%
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates

Bioventus (BVS) delivered earnings and revenue surprises of 33.33% and 2.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 days ago

BVS
+3.19%
Bioventus: Q1 Earnings Snapshot

DURHAM, N.C. (AP) — Bioventus Inc. BVS) on Tuesday reported a loss of $2.6 million in its first quarter. On a per-share basis, the Durham, North Carolina-based company said it had a loss of 4 cents.

Associated Press Finance 3 days ago

BVS
+3.19%
Bioventus Reports First Quarter Financial Results

Q1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0%First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-year periodNon-GAAP earnings* of $0.08 per share increased 33%Company reiterated revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financ

GlobeNewswire 3 days ago

BVS
+3.19%
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-8

GlobeNewswire 11 days ago

BVS
+3.19%
Bioventus Inc. (NASDAQ:BVS) On The Verge Of Breaking Even

Bioventus Inc. ( NASDAQ:BVS ) is possibly approaching a major achievement in its business, so we would like to shine...

Simply Wall St. 17 days ago

BVS
+3.19%
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now

Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks last month

BVS
+3.19%
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know

Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks last month

BVS
+3.19%
Bioventus Full Year 2024 Earnings: Beats Expectations

Bioventus ( NASDAQ:BVS ) Full Year 2024 Results Key Financial Results Revenue: US$573.3m (up 12% from FY 2023). Net...

Simply Wall St. last month

BVS
+3.19%
Q4 2024 Bioventus Inc Earnings Call

Q4 2024 Bioventus Inc Earnings Call

Thomson Reuters StreetEvents last month

BVS
+3.19%
Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ...

Bioventus Inc (BVS) reports robust financial performance with significant revenue increases and strategic debt repayment, setting optimistic guidance for 2025.

GuruFocus.com last month

BVS
+3.19%
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates

Bioventus (BVS) delivered earnings and revenue surprises of 66.67% and 5.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

BVS
+3.19%
Bioventus: Q4 Earnings Snapshot

The Durham, North Carolina-based company said it had a loss of less than 1 cent on a per-share basis. Earnings, adjusted for non-recurring costs, came to 15 cents per share. The company posted revenue of $153.6 million in the period.

Associated Press Finance last month

BVS
+3.19%
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results

Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from operations of $19.3 million increased 86.3%Provides full-year 2025 financial guidance reflecting continued above market revenue growth and continued operating margin expansion DURHAM, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, to

GlobeNewswire last month

BVS
+3.19%
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial

GlobeNewswire 2 months ago

BVS
+3.19%
Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 2 months ago

RXRX

BVS
+3.19%
With 32% ownership, Bioventus Inc. (NASDAQ:BVS) has piqued the interest of institutional investors

Key Insights Institutions' substantial holdings in Bioventus implies that they have significant influence over the...

Simply Wall St. 3 months ago

BVS
+3.19%
Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 15, 2025. About Biovent

GlobeNewswire 3 months ago

BVS
+3.19%

Performance Overview

Return	BVS	S&P 500 (^GSPC)
YTD	-35.24%	-3.70%
1-Year	+34.92%	+9.18%
3-Year	-22.11%	+37.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bioventus Inc. (BVS)

Bioventus First Quarter 2025 Earnings: EPS Beats Expectations

Bioventus Inc (BVS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Divestitures

Q1 2025 Bioventus Inc Earnings Call

Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates

Bioventus: Q1 Earnings Snapshot

Bioventus Reports First Quarter Financial Results

Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

Bioventus Inc. (NASDAQ:BVS) On The Verge Of Breaking Even

Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now

Bioventus (BVS) Upgraded to Buy: Here's What You Should Know

Bioventus Full Year 2024 Earnings: Beats Expectations

Q4 2024 Bioventus Inc Earnings Call

Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ...

Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates

Bioventus: Q4 Earnings Snapshot

Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results

Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?

With 32% ownership, Bioventus Inc. (NASDAQ:BVS) has piqued the interest of institutional investors

Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Performance Overview